NCT00771147已完成不适用
Prospective Open-label Non-interventional, Non-controlled Multi Observational and Pharmaco-economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar® Treatment Under Daily-life Treatment Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 71
- 主要终点
- Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculated
研究概览
简要总结
Evaluation of the efficacy and safety of Nexavar ® in advanced Renal Cell Carcinoma (RCC) and calculation of related medical costs.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with diagnosis of advanced RCC and decision taken by the investigator to prescribe Nexavar®. The patients should have sufficient knowledge of French or Dutch to be able to participate in the Study
排除标准
- •Exclusion criteria must be read in conjunction with the Belgian product information
研究组 & 干预措施
Group 1
干预措施: Sorafenib (Nexavar, BAY43-9006) (Drug)
结局指标
主要结局
Proportion of patients who are progression-free at one year according to the RECIST criteria. The proportion of patients who are progression-free at 1, 3, 6 and 9 months will also be calculated
时间窗: At 1, 3, 6 and 9 months and after one year
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Nexavar Dosing in Renal Cancer Patients in "Real-life" SettingCarcinoma, Renal CellNCT01557127Bayer205
已完成
不适用
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access ProgramCarcinoma, Renal CellNCT01412671Bayer117
尚未招募
2 期
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell CancerRenal Cell CarcinomaClear Cell Renal Cell CarcinomaNCT04958473Tianjin Medical University Second Hospital40
已完成
2 期
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous InvasionMetastatic Renal Cell CarcinomaNon-metastatic Renal Cell CarcinomaRenal Cell CarcinomaNCT03494816Scottish Clinical Trials Research Unit24
已完成
2 期
Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCCAdvanced Hepatocellular CarcinomaNCT01897610GC Cell Corporation40